CYP2C9*8is prevalent among African–Americans: implications for pharmacogenetic dosing
Published 2009 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
CYP2C9*8is prevalent among African–Americans: implications for pharmacogenetic dosing
Authors
Keywords
-
Journal
PHARMACOGENOMICS
Volume 10, Issue 8, Pages 1243-1255
Publisher
Future Medicine Ltd
Online
2009-08-10
DOI
10.2217/pgs.09.71
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Kidney Function Influences Warfarin Responsiveness and Hemorrhagic Complications
- (2009) N. A. Limdi et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Estimation of the Warfarin Dose with Clinical and Pharmacogenetic Data
- (2009) NEW ENGLAND JOURNAL OF MEDICINE
- A Genome-Wide Association Study Confirms VKORC1, CYP2C9, and CYP4F2 as Principal Genetic Determinants of Warfarin Dose
- (2009) Fumihiko Takeuchi et al. PLoS Genetics
- Warfarin Pharmacogenetics: CYP2C9 and VKORC1 Genotypes Predict Different Sensitivity and Resistance Frequencies in the Ashkenazi and Sephardi Jewish Populations
- (2008) Stuart A. Scott et al. AMERICAN JOURNAL OF HUMAN GENETICS
- CYP4F2 genetic variant alters required warfarin dose
- (2008) M. D. Caldwell et al. BLOOD
- VKORC1 Asp36Tyr warfarin resistance marker is common in Ethiopian individuals
- (2008) E. Aklillu et al. BLOOD
- Regulatory polymorphism in vitamin K epoxide reductase complex subunit 1 (VKORC1) affects gene expression and warfarin dose requirement
- (2008) D. Wang et al. BLOOD
- The largest prospective warfarin-treated cohort supports genetic forecasting
- (2008) M. Wadelius et al. BLOOD
- Use of Pharmacogenetic and Clinical Factors to Predict the Therapeutic Dose of Warfarin
- (2008) BF Gage et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Dosing Algorithms to Predict Warfarin Maintenance Dose in Caucasians and African Americans
- (2008) H Schelleman et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Warfarin therapy: in need of improvement after all these years
- (2008) Stephen E Kimmel EXPERT OPINION ON PHARMACOTHERAPY
- Pharmacodynamic resistance to warfarin is associated with nucleotide substitutions inVKORC1
- (2008) D. J. HARRINGTON et al. JOURNAL OF THROMBOSIS AND HAEMOSTASIS
- Multiple genetic alterations in vitamin K epoxide reductase complex subunit 1 gene (VKORC1) can explain the high dose requirement during oral anticoagulation in humans
- (2008) L. BODIN et al. JOURNAL OF THROMBOSIS AND HAEMOSTASIS
- VKORC1polymorphisms, haplotypes and haplotype groups on warfarin dose among African–Americans and European–Americans
- (2008) Nita A Limdi et al. PHARMACOGENOMICS
- Ethnic differences in warfarin maintenance dose requirement and its relationship with genetics
- (2008) Hedi Schelleman et al. PHARMACOGENOMICS
- Dosing algorithm for warfarin using CYP2C9 and VKORC1 genotyping from a multi-ethnic population: comparison with other equations
- (2008) Alan HB Wu et al. PHARMACOGENOMICS
- Influence ofCYP2C9andVKORC1on warfarin dose, anticoagulation attainment and maintenance among European–Americans and African–Americans
- (2008) Nita A Limdi et al. PHARMACOGENOMICS
- Warfarin Pharmacogenetics
- (2008) Nita A Limdi et al. PHARMACOTHERAPY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now